Society for Endocrinology

CONTENTS

VOLUME 24 NUMBER 1

ISSN 1351-0088 (PRINT)
ISSN 1479-6821 (ONLINE)

REVIEW

Animal models of medullary thyroid cancer: state of the art and view to the future R1–R12
Giovanni Vitale, Germano Gaudenzi, Luisa Circelli, Marco F Manzoni, Andrea Bassi, Niccolò Fioritti, Antongiulio Faggiano, Annamaria Colao & on behalf of NIKE Group

RESEARCH

Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma *in vivo* 1–15
Misu Lee, Ninelia Minaskan, Tobias Wiedemann, Martin Irmler, Johannes Beckers, Behrooz H Yousefi, Georgios Kaissis, Rickmer Braren, Iina Laitinen & Natalia S Pellegata

Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2 17–30
K M Biernacka, R A Persad, A Bahl, D Gillatt, J M P Holly & C M Perks

***Prkar1a* gene knockout in the pancreas leads to neuroendocrine tumorigenesis** 31–40
Emmanouil Saloustros, Paraskevi Salpea, Matthew Starost, Sissi Liu, Fabio R Faucz, Edra London, Eva Szarek, Woo-Jin Song, Mehboob Hussain & Constantine A Stratakis

A six-genotype genetic prognostic model for papillary thyroid cancer 41–52
Xiaopei Shen, Rengyun Liu & Mingzhao Xing

Differential roles of RET isoforms in medullary and papillary thyroid carcinomas 53–69
Eric Y Lian, Sarah M Maritan, Jessica G Cockburn, Katayoon Kasaian, Mathieu J F Crupi, David Hurlbut, Steven J M Jones, Sam M Wiseman & Lois M Mulligan

RESEARCH LETTER

***De novo* mutation in *MEN1* is not associated with parental somatic mosaicism** L1–L3
Yael Laitman, Anat Jaffe, Hagit Schayek & Eitan Friedman

LETTER TO THE EDITOR

Targeting PP2A to overcome enzalutamide resistance in AR+ breast tumors L5–L6
Ion Cristóbal, Blanca Torrejón, Manuel Pedregal, Federico Rojo & Jesús García-Foncillas

ACKNOWLEDGEMENT

Acknowledgement to reviewers A1–A6

1351-0088(201701)24:1;1-#

FSC www.fsc.org MIX Paper from responsible sources FSC™ C013985

Society for Endocrinology